Aressy

Researchers are evaluating the effects of Mindfulness-Based Stress Reduction (MBSR) meditation on cardiac patients who have undergone cardiac rehabilitation. Many of these patients experience anxiety and depression, which can reduce their quality of life and interfere with their participation in rehabilitation programs. This study aims to assess the medium- and long-term impact of MBSR on anxiety and depression symptoms in this population. The study compares two approaches: a conventional cardiac rehabilitation program that includes exercise training and educational workshops daily for four weeks, and a cardiac rehabilitation program combined with MBSR meditation. The MBSR program consists of eight weekly group sessions lasting 2 hours and 30 minutes each, daily 45-minute personal meditation practice at home, and an intensive day between the 6th and 7th sessions to deepen mindfulness practices. Participants will be assessed at the start and after 12 months using the Hospital Anxiety and Depression Scale (HADS) to measure changes in anxiety and depression levels. Throughout the study, researchers will monitor participants' progress and adherence to the programs. The total participation includes the rehabilitation period and follow-up assessments to evaluate mental health outcomes over time.

Bronchiectasis is a chronic lung condition where parts of the bronchial tubes become permanently widened, leading to mucus buildup, infections, and ongoing inflammation. Managing this disease often includes respiratory physiotherapy to help clear mucus. However, accessing this therapy regularly can be difficult due to time, location, and availability of trained professionals. Researchers are evaluating the long-term use of the SIMEOX device, which uses brief air pressure pulses to help loosen and move mucus, combined with remote physiotherapy, to improve the quality of life and reduce lung flare-ups in adults with non-cystic fibrosis bronchiectasis. The study compares two groups: one using the SIMEOX device daily at home along with remote physiotherapy sessions, and a control group receiving enhanced standard care plus remote physiotherapy. The remote physiotherapy is delivered monthly for the first three months and then every three months afterward. The study lasts on average 24 months, allowing assessment of the device's effects over the mid and long term. Participants will be monitored through quality of life questionnaires and tracking of pulmonary exacerbations during the study. Evaluations include respiratory assessments and ensuring participants can use the device and follow procedures. The main outcomes measured are changes in respiratory quality of life after six months and the annual rate of lung exacerbations over the full study period. Safety and treatment adherence will also be continuously reviewed throughout participation.